These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31767364)

  • 1. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma.
    Levinsky NC; Wima K; Morris MC; Ahmad SA; Shah SA; Starnes SL; Van Haren RM;
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2555-2566. PubMed ID: 31767364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
    Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.
    Marks JL; Hofstetter W; Correa AM; Mehran RJ; Rice D; Roth J; Walsh G; Vaporciyan A; Erasmus J; Chang J; Maru D; Lee JH; Lee J; Ajani JA; Swisher SG
    Ann Thorac Surg; 2012 Oct; 94(4):1126-32; discussion 1132-3. PubMed ID: 22921233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of thoracic versus cervical anastomosis on anastomotic leak among patients who undergo esophagectomy after neoadjuvant chemoradiation.
    Chidi AP; Etchill EW; Ha JS; Bush EL; Yang SC; Battafarano RJ; Broderick SR
    J Thorac Cardiovasc Surg; 2020 Oct; 160(4):1088-1095. PubMed ID: 32299695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.
    Corsini EM; Foo WC; Mitchell KG; Zhou N; Maru DM; Ajani JA; Hofstetter WL; ; Correa AM; Antonoff MB; Lin SH; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL
    J Thorac Cardiovasc Surg; 2021 Nov; 162(5):1404-1412.e2. PubMed ID: 33010880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients.
    Azab B; Amundson JR; Picado O; Ripat C; Macedo FI; Franceschi D; Livingstone AS; Yakoub D
    Ann Surg Oncol; 2019 Mar; 26(3):861-868. PubMed ID: 30311162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
    Algan O; Coia LR; Keller SM; Engstrom PF; Weiner LM; Schultheiss TE; Hanks GE
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):753-61. PubMed ID: 7790262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation.
    Spector R; Zheng Y; Yeap BY; Wee JO; Lebenthal A; Swanson SJ; Marchosky DE; Enzinger PC; Mamon HJ; Lerut A; Odze R; Srivastava A; Agoston AT; Tippayawang M; Bueno R;
    Semin Thorac Cardiovasc Surg; 2015; 27(2):205-15. PubMed ID: 26686448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
    Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
    J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.